Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cabozantinib arm |
| ||
| non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cabozantinib monotherapy | Drug | Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). |
|
| Measure | Description | Time Frame |
|---|---|---|
| 6 months Real-World Response Rate | From start of index treatment until 6 months of follow up or end of the treatment or death whichever occurs first |
| Measure | Description | Time Frame |
|---|---|---|
| Real-World Overall Response Rate | From start of index treatment until end of the treatment or death whichever occurs first | |
| Overall Survival | From start of index treatment until death or end of the study whichever occurs first |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
US Oncology network
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ipsen Medical Director | Ipsen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| McKesson Life Sciences | The Woodlands | Texas | 77380 | United States |
Not provided
Not provided
Not provided
Not provided
|
| All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC | Drug | As per authorized FDA label in advanced RCC |
|
| Real-World Duration of Response | From date of index treatment response and the earliest date of progressive disease |
| Real-World Progression Free Survival | From start of index treatment until the earliest of death, end of study database, or evidence of Progressive Disease |
| Time to treatment discontinuation | From start of index treatment until treatment discontinuation |
| Treatment dose reductions | Number of patients who had dose reduction/change as compared to the starting dose during index period | From start of index treatment until treatment discontinuation |
| Treatment duration | From start of index treatment until treatment discontinuation |
| Rate of hospitalisations | Number of patients who had been hospitalized (with reason of hospitalization when available) | From start of index treatment until treatment discontinuation |
| Drug discontinuation due to its toxicity | Number of patients discontinuing index regimens due to its toxicity | From start of index treatment until treatment discontinuation (through study completion) |
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C558660 | cabozantinib |
Not provided
Not provided
Not provided